Skip to main content
SpringerLink
Log in

Dopaminagonisten zur Schizophrenie-Behandlung: Ein neues therapeutisches Wirkprinzip?

  • Conference paper
Biologische Psychiatrie

  • 79 Accesses

Zusammenfassung

Die „ Dopaminhypothese der Schizophrenie“ postuliert, daß eine funktioneile Überaktivität der dopaminergen Neurotransmission zumindest der Entstehung akuter schizophrener Symptome zugrundeliegt (Van Rossum 1966; Meltzer u. Stahl 1976). Sie stützt sich auf die Entdeckung der antipsychotischen Wirksamkeit der klassischen Neuroleptika vom Chlorpromazin-Typ, deren Wirkmechanismus heute allgemein auf den Dopamin-D2-Rezeptor-Antagonismus zurückgeführt wird, und diese Auffassung wird auch durch neuere PET-Befunde gestützt (Farde et al. 1988).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Andén NE, Golembiowska-Nikitin K, Thornström U (1982) Selectivestimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933 respectively. Naunyn-Schmiedebergs Arch Pharmacol 321: 100–104

    Article  PubMed  Google Scholar 

  • Andén NE, Grabowska-Andén M, Liljenberg B (1983) Demonstration of autoreceptors and dopamine neurons in different brain regions of rats treated with gammabutyrolactone. J Neural Transm 58: 143–152

    Article  PubMed  Google Scholar 

  • Arnt J, Hyttel J (1990) Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques. J Neural Transm Gen Sect 80(1): 33–50

    Article  PubMed  CAS  Google Scholar 

  • Carlsson A (1975) Receptor mediated control of dopamine metabolism. In: Usdin E, Bunney WE (eds.) Pre- and postsynaptic receptors. Marcel Dekker, New York, pp 49–65

    Google Scholar 

  • Carlsson A (1985) Pharmacological properties of presynaptic dopamine receptor agonists. In: Casey et al. (eds) Dyskinesia — Research and treatment. Psychopharmacology (Suppl) 2: 31–38

    Google Scholar 

  • Carpenter WT jr, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11 (3): 440–452

    PubMed  Google Scholar 

  • Clark D, Hjorth S, Carlsson A (1985) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62: 1–52

    Article  PubMed  CAS  Google Scholar 

  • Corsini GU, Del Zompo M, Manconi S, Cianchetti C, Mangoni A, Gessa GL (1977a) Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv Biochem Psychopharmacol 16: 645–648

    CAS  Google Scholar 

  • Corsini GU, Del Zompo M, Manconi S, Piccardi MP, Onali PL, Mangoni A (1977b) Evidence for dopamine receptors in the human brain mediating sedation and sleep. Life Sci 20: 1613–1618

    Article  CAS  Google Scholar 

  • Creese I (1987) Biochemical properties of CNS dopamine receptors. In: Meltzer HY (ed) Psychopharmacology: The third generation of progress. Raven Press, New York, pp 257–264

    Google Scholar 

  • Cutler NR, Jeste DV, Karoum F, Wyatt RJ (1982) Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients. Life Sci 30: 753–756

    Article  PubMed  CAS  Google Scholar 

  • Deakin JF, Slater P, Simpson MD et al. (1989) Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52(6): 1781–1786

    Article  PubMed  CAS  Google Scholar 

  • Douglas CJ (1900) Hypnotic action of apomorphine without nausea. Mercks Arch 11: 212–213

    Google Scholar 

  • Farde L, Wiesel F-A, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45(1): 71–76

    Article  PubMed  CAS  Google Scholar 

  • Feldman F, Susselman S, Barrera SE (1945) A note on apomorphine as a sedative. Am J Psychiatr 102: 403–405

    PubMed  CAS  Google Scholar 

  • Ferrier IN, Johnstone EC, Crow TJ (1984) Clinical effects of apomorphine in schizophrenia. Br. J Psychiatr 144: 341–348

    Article  CAS  Google Scholar 

  • Hjorth S, Carlsson A (1987) Postsynaptic dopamine (DA) receptor stimulator properties of the putative autoreceptor-selective agonist B-HT 920 uncovered by co-treatment with the D1-agonist SKF 38393. Psychopharmacology (Berlin) 93: 534

    Article  CAS  Google Scholar 

  • Jeste DV, Zalcman S, Weinberger DR, Cutler NR, Bigelow LB, Kleinman JE, Rogol A, Wyatt RJ (1983) Apomorphine response and subtyping of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatr 7: 83–88

    Article  CAS  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796

    Article  PubMed  CAS  Google Scholar 

  • Kim JS, Kornhuber HH, Schmidt-Burgk W, Holzmüller B (1980) Low cerebrospinal fluid glutamate in schizophrenics and a new hypothesis on schizophrenia. Neurosci Lett 20: 379–382

    Article  PubMed  CAS  Google Scholar 

  • Kissling W, Mackert A, Bäuml J, Lauter H (1990) Erste klinische Erfahrungen mit SND 919 — einem neuen Dopamin-Autorezeptor-Agonisten. Fortschr Neurol Psychiat 58 (Sonderheft 1): 17

    Google Scholar 

  • Klimke A, Klieser E (1991) Zur Wirksamkeit der neuroelektrischen Therapie (NET) pharmakotherapeutisch resistenter endogener Psychosen. Fortschr Neurol Psychiatr 58: 53–59

    Article  Google Scholar 

  • Klimke A, Klieser E (1991a) The treatment of positive and negative schizophrenic symptoms with dopamine agonists. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Klimke A, Klieser E (1991b) The antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol) — results of an open clinical study. Pharmacopsychiatry 24: 107–112

    Article  CAS  Google Scholar 

  • Kornhuber J, Fischer EG (1982) Glutamate acid diethyl ester induces catalepsy in rats. A new model for schizophrenia? Neurosci Lett 34: 325–329

    CAS  Google Scholar 

  • Levy MI, Davis BM, Mohs RC, Kendler KS, Mathé AA, Trigos G, Horvath TB, Davis KL (1984) Apomorphine and schizophrenia. Arch Gen Psychiatry 41: 520–524

    Article  PubMed  CAS  Google Scholar 

  • Lipka G, Wiedemann K, Benkert O, Holsboer F (1988) Presynaptic dopamine receptor agonist (B-HT 920) treatment of schizophrenia. Psychopharmacology (Suppl) 96: 333

    Google Scholar 

  • Meltzer HY (1980) Relevance of dopamine autoreceptors for psychiatry. Preclinical and clinical studies. Schizophr Bull 6: 456–475

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Stahl M (1976) The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2: 19

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Kolakowska T, Robertson A, Tricou BJ (1983) Effect of low-dose bromocriptine in treatment of psychosis: The dopamine autoreceptor-stimulation strategy. Psychopharmacology 81: 37–41

    Article  PubMed  CAS  Google Scholar 

  • Roth RH (1979) Dopamine autoreceptors: Pharmacology, function and comparison with postsynaptic dopamine receptors. Commun Psychopharmacol 3: 429–445

    PubMed  CAS  Google Scholar 

  • Seyfried CA, Greiner HE, Haase AF (1989) Biochemical and functional studies on EMD 49980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems. Eur J Pharmacol 160: 31–41

    Article  PubMed  CAS  Google Scholar 

  • Smith RC, Tamminga C, Davis JM (1977) Effect of apomorphine on schizophrenic symptoms. J Neural Transm 40: 171–176

    Article  PubMed  CAS  Google Scholar 

  • Syvälahti EKG, Säkö E, Scheinin M, Pihlajamäki P, Hietala J (1986) Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics. Br J Psychiatry 148: 204–208

    Article  PubMed  Google Scholar 

  • Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL (1986) Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry 43: 398–402

    Article  PubMed  CAS  Google Scholar 

  • Tamminga CA, Schaffer MH (1979) Treatment of schizophrenia with ergot derivatives. Psychopharmacology 66: 239–242

    Article  PubMed  CAS  Google Scholar 

  • Tamminga CA, Schaffer MH, Smith RC, Davis JM (1978) Schizophrenic symptoms improve with apomorphine. Science 200: 567–568

    Article  PubMed  CAS  Google Scholar 

  • Van Rossum JM (1966) The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160: 492–494

    PubMed  Google Scholar 

  • Wöller W, Tegeler J (1983) Späte extrapyramidale Hyperkinesen. Klinik — Prävalenz — Pathophysiologie. Fortschr Neurol Psychiat 51: 131–157

    Article  PubMed  Google Scholar 

Download references

Authors
  1. A. Klimke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Klieser
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik und Poliklinik, Freien Universität Berlin, Eschenallee 3, D-1000, Berlin 19, Deutschland

    Wolfgang Gaebel (Oberarzt) (Oberarzt)

  2. Psychiatrische Klinik der Universität, Füchsleinstraße 15, D-8700, Würzburg, Deutschland

    Gerd Laux (Oberarzt) (Oberarzt)

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Klimke, A., Klieser, E. (1992). Dopaminagonisten zur Schizophrenie-Behandlung: Ein neues therapeutisches Wirkprinzip?. In: Gaebel, W., Laux, G. (eds) Biologische Psychiatrie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77086-9_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77086-9_48

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-54784-6

  • Online ISBN: 978-3-642-77086-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation